Search

Transformative innovation policy (TIP) implies not only new directionality for innovation policy but also rethinking its means and scope. This requires further investigation into the role of horizontal and cross-sectoral policy programmes that may be relevant for upscaling innovation and destabilising regimes. This paper studies the national implementation, in Finland, of the European Union (EU) programme for COVID-19 recovery, the Recovery and Resilience Facility (RRF), as an example of a cross-sectoral policy programme. It is of interest, because the EU has set certain conditions related to sustainability transitions for the RRF. Using a transformative policy mix approach, the paper finds that the Finnish RRF Programme lists many policy measures that can be regarded as having a transformative intent. These include upscaling innovative sustainability niches and destabilising existing practices. Yet, we also found that there is a risk that cross-sectoral programmes fail to find overall transformative visions and fund multiple potentially competing technological pathways instead. [ABSTRACT FROM AUTHOR]

This paper presents findings of a nation-wide study examining the impact of COVID-19 on researchers. Findings indicate that more than half of researchers experienced personal or family mental strain due to COVID-19 pandemic effects. COVID-19 pandemic is being treated as an opportunity by six out of ten researchers in terms of more time for study and planning future research activities (78 per cent). The majority of researchers (73 per cent) believe that Science and Technology will emerge enhanced from the pandemic in the public sphere. Relating our findings with research outcomes of existed surveys, it appears that COVID-19 had a significant impact on researchers' and workers' psychosocial life. Researchers' and scientists' standpoint suggest that Science and Technology will be upgraded in the public dialogue. Finally, researchers viewed the pandemic as an opportunity for more time for study and planning of future research activities while working time, with respect to other countries, decreased the most. [ABSTRACT FROM AUTHOR]

Coronavirus disease 2019 (COVID-19) has been a global disaster, with over 746,312 confirmed cases and still counting in Indonesia, especially Jakarta, which has about 50 per cent asymptomatic confirmed cases. This paper aims to investigate the persistent factors of COVID-19 diagnosis using four scenarios of asymptomatic inclusion. We use Bayesian Logistic Regression to identify the factors of COVID-19 positivity, which can address issues in the traditional approach such as overfitting and uncertainty. This study discovers three main findings: (1) COVID-19 can infect people regardless of age; (2) Among twelve symptoms of coronavirus (COVID-19), five symptoms increase the COVID-19 likelihood, and two symptoms decrease the possibility of COVID-19 infection; and (3) From an epidemiological perspective, the contact history rises the probability of COVID-19, while healthcare workers and people who did travel are less likely to become infected from COVID-19. Therefore given this study, it is essential to be attentive to the people who have the symptoms and contact history. Surprisingly, health care workers and travelers who apply health protocols strictly according to the rules have a low risk of COVID19 infection. [ABSTRACT FROM AUTHOR]

As thousands of 2019 Corona virus disease (Covid-19) clinical trials are continuously getting added to various registries these days, good practices on data sharing and transparency have become one of the prime topics of discussion than ever before. Although trial registration is considered a crucial step, there is a lack of integration between registration and published literature. Trial outcomes are a matter of public interest, but sponsor compliances are not adequate with the recommended guidelines. Although the global recognition of data transparency increases day by day, there is still a long journey to travel. It is high time that scholarly publishing stakeholders should put in a collaborative effort to check author compliance. In this article, we aimed to comprehend and discuss the imperative roles of various scholarly publishing stakeholders in improving clinical trial transparency during this pandemic situation and highlight the changing paradigm towards the pressing need for reporting clinical trial data more effectively. [ABSTRACT FROM AUTHOR]

Developing emergency drugs in time is key to responding to public health emergencies such as the coronavirus disease 2019 (COVID-19) pandemic. This research constructs patent assignee citation networks based on COVID-19 drug patents and applies technology life cycle analysis and social network analysis to examine these networks. The results reveal the evolution and structure of the emergency drug innovation network and identify innovation entities with different research and development (R&D) capabilities or a foundation for cooperation. This study attempts to provide the basis for theories and policies to accelerate R&D of emergency drugs. The key results are as follows: (1) Technologies of the emergency drug innovation network show fluctuating growth aligned closely with public health emergencies. (2) The network presents a sparse structure with many active factions, whose members have the advantage of cooperating. (3) Three types of innovation entities are identified: the main technology suppliers, potential suppliers of other supporting technologies, and peripheral suppliers of other supporting technologies. [ABSTRACT FROM AUTHOR]

The ongoing COVID-19 emergency clearly presents novel challenges, both in terms of difficulties for maintaining public health and in assuring that governmental responses are ethically sound. Centrally, responses must respect, as best as possible, fundamental human rights and human values. Conflicts among values arise in response to the crisis, and public officials have no choice but to prioritize some while sacrificing others. Utilizing the concepts of effectiveness and legitimacy within the framework of post-normal science (PNS), we investigate and recommend processes and measures to address COVID-19 that support increased public health, while upholding established rights and values. The effectiveness and legitimacy of science-led policymaking requires investigation of how that policy ought to be made (e.g. concepts of policymaking and PNS), as well as how it ought to interact with diversely-constituted publics (e.g. public inclusion in policymaking and policy communication). [ABSTRACT FROM AUTHOR]